- Home
- ISRG vs JNJ Comparison
ISRG vs JNJ Comparison
Compare ISRG & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | JNJ |
|---|---|---|
| Founded | 1995 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.9B | 505.3B |
| IPO Year | 2000 | 1944 |
Fundamental Metrics
Financial Performance| Metric | ISRG | JNJ |
|---|---|---|
| Price | $534.76 | $218.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $609.29 | $209.27 |
| AVG Volume (30 Days) | 1.7M | ★ 7.9M |
| Earning Date | 01-22-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | 21.56 | ★ 71.26 |
| EPS | 7.56 | ★ 10.35 |
| Revenue | $9,612,000,000.00 | ★ $92,149,000,000.00 |
| Revenue This Year | $21.14 | $6.63 |
| Revenue Next Year | $15.00 | $5.49 |
| P/E Ratio | $70.78 | ★ $21.13 |
| Revenue Growth | ★ 22.18 | 5.08 |
| 52 Week Low | $425.00 | $141.50 |
| 52 Week High | $616.00 | $220.11 |
Technical Indicators
Market Signals| Indicator | ISRG | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 68.78 |
| Support Level | $528.00 | $203.85 |
| Resistance Level | $553.74 | $208.98 |
| Average True Range (ATR) | 13.11 | 3.44 |
| MACD | -5.59 | 1.16 |
| Stochastic Oscillator | 10.06 | 91.46 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.